期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

索拉非尼治疗晚期肾癌的现状 被引量：4

暂未订购
导出
摘要 随着临床对肾癌发病机制研究的不断深入,其细胞学、分子生物学领域的不断进展,其细胞信号转导路中的一些关键分子已经成为治疗的靶点,不断有新的分子靶向治疗药物问世,索拉非尼是2005年被美国FDA批准用于晚期肾癌治疗的靶向药物,美国国家综合癌症网络制定的2008年版《肾癌诊治指南》中推荐索拉非尼作为部分患者的一线治疗或者所有患者的二线治疗用药。现就索拉非尼在肾癌晚期的治疗现状、机制及应用前景作一简介。
作者 王英迪 孙凯 姜宏宇
机构地区 吉林省肿瘤医院
出处 《中国医药指南》 2012年第30期448-449,共2页 Guide of China Medicine
关键词 索拉非尼 晚期肾癌
分类号 R737.11 [医药卫生—肿瘤]
  • 相关文献

参考文献8

二级参考文献34

  • 1Lee JT, McCubrey JA. BAY-43-9006 Bayer/Onyx. Curr Opin Investig Drugs, 2003, 4: 757-763.
  • 2Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356:125-134.
  • 3Wilhelm SM, Carter C,Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64: 7099-7109.
  • 4Awada A, Hendlisz A, Git T, et al. Safety and pharmacokinetics of BAY 43 9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer, 2005, 92: 1855-1861.
  • 5Ratain MJ, Eisen T, Stadler WM, et al. Phase Ⅱ placebo controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24; 2505-2512.
  • 6Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oneol, 2002, 20, 289-296.
  • 7Knox JJ, Figlin RA, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. J Clin Oneol, 2007, 25(Suppl) : 241.
  • 8Akaza H, Tsukamoto T, Murai M, et al. Phase Ⅱ study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. JpnJ Clin Oncol, 2007, 37: 755-762.
  • 9Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol, 2008, 158: 592-596.
  • 10Shmidinger M, Vogl UM, Schukro C, et al. Cardiac involvement in patients with sorafenib or sunitinib treatment for metastatic renal cell carcinoma. J Clin Oncol, 2007, 25(Suppl) 293.

共引文献75

同被引文献29

  • 1方基才.甘草泻心汤配合西药治疗化疗引起的呕吐36例疗效观察[J].现代肿瘤医学,2004,12(5):467-467. 被引量：5
  • 2Westwood JA, Darcy PK, Guru PM, :: al. Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopickidney cancer in mice [J]. J Transt Med, 2010, 8(1): 42.
  • 3Hanzly MA, Aboumohamed, Yarla:dda N, et al. High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contem- porary experience [J]. Urology 2014, 83(5): 1129-1134.
  • 4Passalacqua R, Buzio C, Buti S, et al. Phase UI, randomised, multieentre trial ofmainten- ance immunotherapy with low-dose interle- ukin-2 and interferon-alpha for metastatic re- nal cell cancer [J]. Cancer Immunol Immun- other, 2010, 59(4): 553-561.
  • 5Miyaki D,Aikata H,Kan H,et al.Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy〔J〕.J Gastroenterol Hepatol,2013;28(12):1834-41.
  • 6Liu YJ,Zhu GP,Guan XY.Comparison of the NCI-CTCAE version 4.0and version 3.0 in assessing chemoradiation-induced oral mucositis for locally advanced nasopharyngeal carcinoma〔J〕.Oral Oncol,2012;48(6):554-9.
  • 7Abdel-Rahman O,Abdel-Wahab M,Shaker M,et al.Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma〔J〕.Med Oncol,2013;30(3):655.
  • 8闫河峰,车新平,卢建路,崔勇,冀强.小剂量白介素联合5氟尿嘧啶治疗晚期肾癌疗效观察[J].中国实用医药,2008,3(12):138-139. 被引量：1
  • 9黎介寿.对肠功能障碍的再认识[J].肠外与肠内营养,2008,15(6):321-322. 被引量：100
  • 10张奇夫,汪清,付成,周昌东,金刚,田玉新,刘一,王英迪.索拉非尼治疗老年晚期肾癌患者有效性与安全性的初步评价[J].中华泌尿外科杂志,2010,31(1):12-14. 被引量：10

引证文献4

二级引证文献26

中国医药指南
2012年 第30期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部